Oxford Nanopore Technolo... Share Discussion Threads

[bamboo2] 21/6/2024 07:42

dawneyd, I searched again, then finally wrote to the co.

It's 5th October.

Thanks for prompting this conversation.

I will amend the header.

[bamboo2] 20/6/2024 09:17

dawneyd, thanks. I do get your 'no date' interpretation as well.

What leaves me thinking issue date for LAT's is 22/6/21 is the fact that I have searched everywhere for an alternate issue date, but have not found anything yet!

[dawneyd] 20/6/2024 08:55

bamboo2 - I know you were trying to get discussion on this early, which is good as it maybe wasn't clear. I still think your reading that para on p178 wrong, the semi-colon after 'company' separates (a) from (b), and the LAT are not part of the equity award. The 'shareholders approved:' both of those things separately is my reading, so the 22 June date is only the equity award issue ('grant') and no date given for the LAT.
I'm sticking with October in my thinking as it was dependent on the IPO happening (hehe - unless the company issue RNS Monday saying I'm wrong and there just been cancelled :)

[p1nkfish] 20/6/2024 08:28

Price, currently, doesn't signal any imminent change?

[bamboo2] 20/6/2024 07:40

dawneyd, as you can see from earlier posts, I have been open about the ambiguity in the registration document, and have tried to get others to look into what they think might be the actual date of their expiry.

If you want a definitive answer, it's probably simpler to email IR at the co, as I would guess that this info will be freely available.

====================
Quote, use p 178 for full text

"On 9 June 2021, the shareholders approved: (a) a conditional retention equity award ... ... On 22 June 2021, awards under this plan were granted to the executive directors of the company; and (b) a limited anti-takeover non-voting share of £1.00 in the capital of the Company (a “LAT Share”)."

====================

Then read on further,

"The rights attributable to a LAT Share will cease (and that LAT Share will be capable of being repurchased or cancelled by the Company) on the earlier of: (a) the date falling three years after the date of the issue
of that LAT Share;..."etc

[dawneyd] 19/6/2024 21:53

bamboo2 - going back to your December post with page number that 22 June date looks for point (a) there only, no? For the 'conditional retention equity award'? It has 'On 22 June 2021, awards under this plan were granted to the executive directors of the company; and'
Then its point (b) after that for the LAT, with no date.
I always thought October flotation for the expiry start, which you also mentioned in that post.

[dawneyd] 19/6/2024 21:34

seball - thanks for confirming that, I had already guessed from the format it was likely. It's also given you complete nonsense!

Please, everyone, if you are going to use an AI/chatbot rather than reading the RNS and docs yourself then you have to state a) which robot you used, b) the exact question you gave it, and then c) post the answer. That way everyone else can see the result in the right context and then check it themselves. You can't just post up a "quote" and not make that clear. Cheers. -/end rant ;)

[seball] 19/6/2024 19:48

Hi it was what came out of chat gpt. Thanks

[dawneyd] 19/6/2024 17:26

bamboo2 - I already know whats in this thread, and I know what 'LAT' means for ONT. My specific question to seball still stands as the post doesnt make sense.

[bamboo2] 19/6/2024 17:07

The LAT shares and their unintended consequences were discussed earlier in the thread.

The header refers to the ambiguity of expiry dates. The flotation paperwork clearly states three years from issue, however it is the issue date that is/has been unclear.

Clive Brown gave up his LAT share when he declined re-election to the BOD earlier this year.

dawneyd, type LAT into the 'search thread' box at the top of the header.

[dawneyd] 19/6/2024 16:44

seball - what are "Limited Availability Tranche" shares, never heard that before?

And is the second part of the post with the dates jist you paraphrasing from an AGM notice, or did you get all of it from an AI/chatbot request? Any links please?

[minsky] 19/6/2024 13:34

So they've already expired?

[seball] 19/6/2024 13:04

Oxford Nanopore Technologies PLC's Limited Availability Tranche (LAT) shares are set to expire at the conclusion of the company's 2024 Annual General Meeting or by the close of business on September 12, 2024, whichever comes first​. .

[p1nkfish] 19/6/2024 12:44

Currently it could rally 20% and still not break the downtrend.

If the ultimate target is towards 300p+ then missing the first 20p to de-risk an entry won't be existential.

What's the rush until it's confirmed to have turned?

[takeiteasy] 19/6/2024 12:41

any possible triggers out there to stem the tide? I've been waiting a long time to find this bottom...

[seball] 19/6/2024 12:32

ok thanks Bamboo, have you a link?

[seball] 19/6/2024 11:02

Hi Bamboo, I have heard dates of August and October for the expiry of LAT shares. In any case this is very cheap at this price.

[minsky] 19/6/2024 08:50

As things stand just now ONT would be around position 276 of the FTSE 350.

[bamboo2] 19/6/2024 07:15

By my reckoning there are only two more trading days until the LAT shares expire.

Shorts can no longer rely on the fact that there is little chance of corporate activity.

We may eventually see ONT included in FTSE 100/250, and passive trackers, and funds that precluded anti-takeover co's could become buyers.

[bamboo2] 15/6/2024 09:22

Most of the presentations from LC2024 uploaded now, of particular interest are those from the Clinical Day. Gordon Sanghera suggested that commercial traction from clinical applications will begin in 2025, providing an alternative income stream for ONT.

===========================================

A prospective clinical pilot study was conducted in ICU patients with respiratory failure, using a unified respiratory metagenomic (RMg) workflow encompassing DNA and RNA sequencing.

Respiratory metagenomics in clinical service


PulseNet — the national molecular surveillance network of over 80 public health labs in the United States, connects food, water, and one-health related illnesses that may be part of an outbreak —fully implemented WGS in 2019. WGS data is comprehensive: antimicrobial resistance, virulence markers, serotype markers, plasmids, and core and accessory genes are all characterized as part of the WGS workflow. Additionally, sequence data is portable and is shared between United States federal agencies, over 80 PulseNet International member countries, and public repositories, including the National Center for Biotechnology Information (NCBI). Currently, PulseNet USA sequences approximately 65,000 Salmonella, Escherichia, Listeria, Vibrio, Campylobacter, and Shigella isolates annually.

Whole-genome sequencing in PulseNet foodborne molecular surveillance systems


Vid from recent Genomics England event.
Empowering comprehensive sequencing at scale [with Greg Elgar]

[p1nkfish] 14/6/2024 13:56

Better off waiting for confirmation on the turn, miss the first 15%?

[takeiteasy] 14/6/2024 08:25

Still can't seem to find any safe bottom to enter here - will have to be super patient indeed. American rival share price still rather sour - does not help sentiment... nai etc

[brucie5] 14/6/2024 08:11

Wise words.